Inhibition of cytochrome P450 3A4 by a pyrimidineimidazole: Evidence for complex heme interactions

Chemical Research in Toxicology

Volumn 19, Issue 12, 2006, Pages 1650-1659

  Hutzler, J Matthew ^d   Melton, Roger J ^d   Rumsey, Jeanne M ^d   Schnute, Mark E ^a   Locuson, Charles W ^b   Wienkers, Larry C ^c  

^a PFIZER INC   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c AMGEN INC   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBENE; CYTOCHROME P450 3A4; DIMER; HEME; IMIDAZOLE DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; KETOCONAZOLE; MIDAZOLAM; MONOMER; N [3 [(3,4 DIHYDROXYBENZYL)(METHYL)AMINO]PROPYL] N [2 (1H IMIDAZOL 1 YL) 6 METHYLPYRIMIDIN 4 YL]GLYCINAMIDE; PHENYL GROUP; PYRIMIDINE DERIVATIVE; TESTOSTERONE;

ARTICLE; COMPETITIVE INHIBITION; COMPLEX FORMATION; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; HYDROXYLATION; KINETICS; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MASS SPECTROMETRY; METABOLISM; METABOLITE; SCREENING; SPECTRAL SENSITIVITY; TIME;

BENZODIOXOLES; CHROMATOGRAPHY, LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; ENZYME INHIBITORS; HEME; HUMANS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; PROTEIN BINDING; PYRIMIDINES; TANDEM MASS SPECTROMETRY;

EID: 33845773873     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx060198m     Document Type: Article

References (50)

1. Blasko, E., Glaser, C. B., Devlin, J. J., Xia, W., Feldman, R. I., Polokoff, M. A., Phillips, G. B., Whitlow, M., Auld, D. S., McMillan, K., Ghosh, S., Stuehr, D. J., and Parkinson, J. F. (2002) Mechanistic studies with potent and selective inducible nitric-oxide synthase dimerization inhibitors. J. Biol. Chem. 277, 295-302.
2. Wrighton, S. A., and Stevens, J. C. (1992) The human hepatic cytochromes P450 involved in drug metabolism. Crit. Rev. Toxicol. 22, 1-21.
3. Guengerich, F. P. (2002) Update information on human P450s. Drug Metab. Rev. 34, 7-15.
4. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. P. (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423.
5. Lomaestro, B. M., and Piatek, M. A. (1998) Update on drug interactions with azole antifungal agents. Ann. Pharmacother. 32, 915-928.
6. Fleishaker, J. C., Herman, B. D., Carel, B. J., and Azie, N. E. (2003) Interaction between ketoconazole and almotriptan in healthy volunteers. J. Clin. Pharmacol. 43, 423-427.
7. Moody, D. E., Walsh, S. L., Rollins, D. E., Neff, J. A., and Huang, W. (2004) Ketoconazole, a cytochrome P450 3A4 inhibitor, markedly increases concentrations of levo-acetyl-alpha-methadol in opioid-naive individuals. Clin. Pharmacol. Ther. 76, 154-166.
8. Schenkman, J. B., Sligar, S. G., and Cinti, D. L. (1981) Substrate interaction with cytochrome P-450. Pharmacol. Ther. 12, 43-71.
9. Schenkman, J. B., and Jansson, I. (1998) Spectral analyses of cytochromes P450. Methods Mol. Biol. 107, 25-33.
10. Racha, J. K., Zhao, Z. S., Olejnik, N., Warner, N., Chan, R., Moore, D., and Satoh, H. (2003) Substrate dependent inhibition profiles of fourteen drugs on CYP3A4 activity measured by a high throughput LCMS/MS method with four probe drugs, midazolam, testosterone, nifedipine and terfenadine. Drug Metab. Pharmacokinet. 18, 128-138.
11. Amacher, D. E., Fasulo, L. M., Charuel, C., Comby, P., and Beaumont, K. (1998) In vitro toxicity of zamifenacin (UK-76,654) and metabolites in primary hepatocyte cultures. Xenobiotica 28, 895-908.
12. Beaumont, K. C., Causey, A. G., Coates, P. E., and Smith, D. A. (1996) Pharmacokinetics and metabolism of zamifenacin in mouse, rat, dog and man. Xenobiotica 26, 459-471.
13. Mansuy, D., Carlier, M., Bertrand, J. C., and Azoulay, E. (1980) Spectral characterization of cytochrome P-450 of a strain of Candida tropicalis grown on tetradecane. Eur. J. Biochem. 109, 103-108.
14. Ortiz de Montellano, P. R. (1995) Inhibition of Cytochrome P450 Enzymes. In Cytochrome P450: Structure, Mechanism, and Biochemistry (Ortiz de Montellano, P. R., Ed.) pp 305-364, Plenum Press, New York.
15. Murray, M., and Reidy, G. F. (1989) In vitro formation of an inhibitory complex between an isosafrole metabolite and rat hepatic cytochrome P-450 PB-B. Drug Metab. Dispos. 17, 449-454.
16. Bertelsen, K. M., Venkatakrishnan, K., Von, Moltke, L. L., Obach, R. S., and Greenblatt, D. J. (2003) Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug Metab. Dispos. 31, 289-293.
17. Chatterjee, P., and Franklin, M. R. (2003) Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab. Dispos. 31, 1391-1397.
18. Yano, J. K., Wester, M. R., Schoch, G. A., Griffin, K. J., Stout, C. D., and Johnson, E. F. (2004) The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution. J. Biol. Chem. 279, 38091-38094.
19. Scott, E. E., and Halpert, J. R. (2005) Structures of cytochrome P450 3A4. Trends Biochem. Sci. 30, 5-7.
20. Ekroos, M., and Sjogren, T. (2006) Structural basis for ligand promiscuity in cytochrome P450 3A4. Proc. Natl. Acad. Sci. U.S.A. 103, 13682-13687.
21. Korzekwa, K. R., Krishnamachary, N., Shou, M., Ogai, A., Parise, R. A., Rettie, A. E., Gonzalez, F. J., and Tracy, T. S. (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37, 4137-4147.
22. Hosea, N. A., Miller, G. P., and Guengerich, F. P. (2000) Elucidation of distinct ligand binding sites for cytochrome P450 3A4. Biochemistry 39, 5929-5939.
23. McMillan, K., Adler, M., Auld, D. S., Baldwin, J. J., Blasko, E., Browne, L. J., Chelsky, D., Davey, D., Dolle, R. E., Eagen, K. A., Erickson, S., Feldman, R. I., Glaser, C. B., Mallari, C., Morrissey, M. M., Ohlmeyer, M. H., Pan, G., Parkinson, J. F., Phillips, G. B., Polokoff, M. A., Sigal, N. H., Vergona, R., Whitlow, M., Young, T. A., and Devlin, J. J. (2000) Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc. Natl. Acad. Sci. U.S.A. 97, 1506-1511.
24. Cohen, L. H., Remley, M. J., Raunig, D., and Vaz, A. D. (2003) In vitro drug interactions of cytochrome p450: an evaluation of fluorogenic to conventional substrates. Drug Metab. Dispos. 31, 1005-1015.
25. Kitz, R. J., Ginsburg, S., and Wilson, I. B. (1967) The reaction of acetylcholinesterase with diethylphosphoryl esters of quaternary and tertiary aminophenols. Mol. Pharmacol. 3, 225-232.
26. Segel, I. H. (1975) Enzyme Kinetics, p 110, John Wiley & Sons, New York.
27. Roberts, A. G., Campbell, A. P., and Atkins, W. M. (2005) The thermodynamic landscape of testosterone binding to cytochrome P450 3A4: ligand binding and spin state equilibria. Biochemistry 44, 1353-1366.
28. Beumel, G. A., Levi, P. E., and Hodgson, E. (1985) Spectral interactions of piperonyl butoxide and isocyanides with purified hepatic cytochrome P-450 from uninduced mice. Gen. Pharmacol. 16, 193-197.
29. Salerno, L., Sorrenti, V., Di Giacomo, C., Romeo, G., and Siracusa, M. A. (2002) Progress in the development of selective nitric oxide synthase (NOS) inhibitors. Curr. Pharm. Des. 8, 177-200.
30. Wang, R. W., Newton, D. J., Liu, N., Atkins, W. M., and Lu, A. Y. (2000) Human cytochrome P-450 3A4: in vitro drug-drug interaction patterns are substrate-dependent. Drug Metab. Dispos. 28, 360-366.
31. Stresser, D. M., Blanchard, A. P., Turner, S. D., Erve, J. C., Dandeneau, A. A., Miller, V. P., and Crespi, C. L. (2000) Substrate-dependent modulation of CYP3A4 catalytic activity: analysis of 27 test compounds with four fluorometric substrates. Drug Metab. Dispos. 28, 1440-1448.
32. Chiba, M., Jin, L., Neway, W., Vacca, J. P., Tata, J. R., Chapman, K., and Lin, J. H. (2001) P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency, and P450 binding spectra. Drug Metab. Dispos. 29, 1-3.
33. Schenkman, J. B. (1970) Studies on the nature of the type I and type II spectral changes in liver microsomes. Biochemistry 9, 2081-2091.
34. Isoherranen, N., Kunze, K. L., Allen, K. E., Nelson, W. L., and Thummel, K. E. (2004) Role of itraconazole metabolites in CYP3A4 inhibition. Drug Metab. Dispos. 32, 1121-1131.
35. Kunze, K. L., Nelson, W. L., Kharasch, E. D., Thummel, K. E., and Isoherranen, N. (2006) Stereochemical aspects of itraconazole metabolism in vitro and in vivo. Drug Metab. Dispos. 34, 583-590.
36. Klungsoyr, J., and Scheline, R. R. (1982) Metabolism of isosafrole and dihydrosafrole in the rat. Biomed. Mass Spectrom. 9, 323-329.
37. Ma, B., Prueksaritanont, T., and Lin, J. H. (2000) Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab. Dispos. 28, 125-130.
38. Zhao, X. J., Jones, D. R., Wang, Y. H., Grimm, S. W., and Hall, S. D. (2002) Reversible and irreversible inhibition of CYP3A enzymes by tamoxifen and metabolites. Xenobiotica 32, 863-878.
39. von Moltke, L. L., Durol, A. L., Duan, S. X., and Greenblatt, D. J. (2000) Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur. J. Clin. Pharmacol. 56, 259-261.
40. Hanioka, N., Ozawa, S., Jinno, H., Tanaka-Kagawa, T., Nishimura, T., Ando, M., and Sawada, Ji, J. (2002) Interaction of irinotecan (CPT-11) and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) with human cytochrome P450 enzymes. Drug Metab. Dispos. 30, 391-396.
41. Atkins, W. M. (2005) Non-Michaelis-Menten kinetics in cytochrome P450-catalyzed reactions. Annu. Rev. Pharmacol. Toxicol. 45, 291-310.
42. Shou, M., Grogan, J., Mancewicz, J. A., Krausz, K. W., Gonzalez, F. J., Gelboin, H. V., and Korzekwa, K. R. (1994) Activation of CYP3A4: evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33, 6450-6455.
43. Mayhew, B. S., Jones, D. R., and Hall, S. D. (2000) An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos. 28, 1031-1037.
44. Dabrowski, M. J., Schrag, M. L., Wienkers, L. C., and Atkins, W. M. (2002) Pyrene-pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site. J. Am. Chem. Soc. 124, 11866-11867.
45. Atkins, W. M. (2004) Implications of the allosteric kinetics of cytochrome P450s. Drug Discovery Today 9, 478-484.
46. Koley, A. P., Buters, J. T., Robinson, R. C., Markowitz, A., and Friedman, F. K. (1995) CO binding kinetics of human cytochrome P450 3A4. Specific interaction of substrates with kinetically distinguishable conformers. J. Biol. Chem. 270, 5014-5018.
47. Koley, A. P., Robinson, R. C., and Friedman, F. K. (1996) Cytochrome P450 conformation and substrate interactions as probed by CO binding kinetics. Biochimie 78, 706-713.
48. Davydov, D. R., Halpert, J. R., Renaud, J. P., and Hui Bon Hoa, G. (2003) Conformational heterogeneity of cytochrome P450 3A4 revealed by high pressure spectroscopy. Biochem. Biophys. Res. Commun. 312, 121-130.
49. Davydov, D. R., Fernando, H., Baas, B. J., Sligar, S. G., and Halpert, J. R. (2005) Kinetics of dithionite-dependent reduction of cytochrome P450 3A4: heterogeneity of the enzyme caused by its oligomerization. Biochemistry 44, 13902-13913.
50. Dickins, M., Elcombe, C. R., Moloney, S. J., Netter, K. J., and Bridges, J. W. (1979) Further studies on the dissociation of the isosafrole metabolite-cytochrome P-450 complex. Biochem. Pharmacol. 28, 231-238.